Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
EAST MILLSTONE, N.J., Feb. 14, 2018 -- Envigo International Holdings, Inc. ("Envigo"), a leading provider of nonclinical contract research services and research models, announced today that the Transaction Agreement with Avista Healthcare Public Acquisition Corp. ("AHPAC") has been terminated by mutual agreement, due to unfavorable market conditions.
About Envigo
Envigo provides mission-critical products and research services for pharmaceutical, crop protection, and chemical companies as well as universities, governments, and other research organizations. The Company is founded on the principle that research partnerships depend on unmatched expertise, unwavering dedication to customer service, and shared goals. Envigo is committed to helping customers realize the full potential of their products and research which contribute to enhancing the lives of people and animals as well as protecting the environment. With over 3,300 employees worldwide, Envigo provides comprehensive scientific expertise and a full service offering in non-clinical research and development, research models and services, regulatory consulting, and analytical support to customers. Envigo’s corporate headquarters are located in New Jersey.
(www.envigo.com)
For enquiries please contact:
Paul Surdez
(732) 873-6682
[email protected]
